Your browser is no longer supported. Please, upgrade your browser.
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own18.60% Shs Outstand5.75M Perf Week2.69%
Market Cap71.79M Forward P/E- EPS next Y-0.33 Insider Trans-0.00% Shs Float5.38M Perf Month20.19%
Income-7.80M PEG- EPS next Q1.06 Inst Own34.10% Short Float4.92% Perf Quarter-5.16%
Sales47.50M P/S1.51 EPS this Y52.30% Inst Trans7.75% Short Ratio5.95 Perf Half Y146.41%
Book/sh-5.42 P/B- EPS next Y-273.70% ROA-16.00% Target Price16.38 Perf Year123.91%
Cash/sh1.19 P/C8.65 EPS next 5Y- ROE23.50% 52W Range3.82 - 12.25 Perf YTD144.08%
Dividend- P/FCF- EPS past 5Y-8.60% ROI-2.50% 52W High-15.92% Beta1.84
Dividend %- Quick Ratio2.50 Sales past 5Y17.80% Gross Margin86.20% 52W Low169.56% ATR0.38
Employees130 Current Ratio2.70 Sales Q/Q-22.80% Oper. Margin-6.60% RSI (14)55.50 Volatility3.00% 3.53%
OptionableNo Debt/Eq- EPS Q/Q-163.50% Profit Margin-16.40% Rel Volume0.08 Prev Close10.28
ShortableYes LT Debt/Eq- EarningsApr 28 AMC Payout- Avg Volume44.57K Price10.30
Recom2.00 SMA203.30% SMA503.79% SMA20044.57% Volume3,816 Change0.19%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Jun-05-21 04:22AM  
May-27-21 07:15PM  
May-17-21 08:12AM  
Apr-29-21 03:30PM  
Apr-28-21 07:25PM  
Apr-26-21 10:51AM  
Apr-22-21 08:00AM  
Apr-14-21 10:34AM  
Apr-09-21 08:00AM  
Mar-18-21 08:00AM  
Mar-17-21 08:00AM  
Mar-11-21 08:00AM  
Mar-02-21 08:00AM  
Feb-25-21 03:30PM  
Feb-24-21 04:05PM  
Feb-18-21 10:57AM  
Feb-17-21 08:30AM  
Feb-15-21 08:30AM  
Feb-01-21 09:05AM  
Jan-19-21 08:00AM  
Jan-05-21 08:00AM  
Dec-24-20 09:14AM  
Dec-22-20 10:22AM  
Dec-21-20 10:13AM  
Dec-17-20 08:42AM  
Dec-16-20 01:31PM  
Dec-15-20 09:57AM  
Dec-14-20 12:59PM  
Dec-11-20 08:34AM  
Dec-10-20 09:40AM  
Dec-09-20 08:33AM  
Dec-08-20 08:56AM  
Dec-07-20 09:27AM  
Dec-04-20 08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 07:42PM  
Dec-01-20 10:06AM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-20-20 10:08AM  
Nov-18-20 11:24AM  
Nov-16-20 08:00AM  
Nov-13-20 11:22AM  
Nov-12-20 08:00AM  
Nov-09-20 10:18AM  
Nov-06-20 10:57AM  
Nov-05-20 11:38AM  
Nov-04-20 12:00PM  
Oct-30-20 02:31PM  
Oct-29-20 07:00AM  
Oct-28-20 06:25PM  
Oct-22-20 08:00AM  
Sep-23-20 08:00AM  
Sep-15-20 08:00AM  
Sep-09-20 11:18AM  
Sep-08-20 08:00AM  
Sep-01-20 10:10AM  
Aug-31-20 05:00PM  
Aug-30-20 09:47AM  
Aug-26-20 08:30AM  
Aug-25-20 08:00AM  
Aug-13-20 08:00AM  
Aug-05-20 12:00PM  
Jul-31-20 12:30PM  
Jul-29-20 06:25PM  
Jul-23-20 11:15AM  
Jul-22-20 08:00AM  
Jul-09-20 08:00AM  
Jun-25-20 10:37AM  
Jun-23-20 06:36PM  
Jun-16-20 10:25AM  
Jun-10-20 06:04PM  
Jun-03-20 09:00AM  
Apr-30-20 08:30PM  
Apr-29-20 06:25PM  
Apr-24-20 08:00AM  
Apr-23-20 08:00AM  
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashman PhilipChief Operating Officer & SVPApr 08Sale9.624543319,379Apr 12 04:56 PM
Ashman PhilipChief Operating Officer & SVPNov 04Buy4.501,3165,92211,957Nov 05 02:46 PM
EISWIRTH RICHARD S JRPresident and CEONov 02Buy4.152,50010,37742,043Nov 04 04:53 PM
Myers C. DanielDirectorAug 20Sale6.735,00033,6505,578Aug 24 04:25 PM